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Background: Previous studies have found an association between psychiatric disorders and vitamin D deficiency,
but most studies have focused on depression. This study aimed to establish the prevalence of vitamin D deficiency
in elderly patients with a wider range of psychiatric diagnoses.
Method: The study included elderly patients (>64 years) referred to a psychiatric hospital in Northern Norway and a
control group from a population survey in the same area. An assessment of psychiatric and cognitive symptoms
and diagnoses was conducted using the Montgomery and Aasberg Depression Rating Scale, the Cornell Scale for
Depression in Dementia, the Mini Mental State Examination, the Clockdrawing Test, and the Mini International
Neuropsychiatric Interview (MINI+), as well as clinical interviews and a review of medical records. The patients’
mean level of 25-hydroxyvitamin D (25(OH)D) and the prevalence of vitamin D deficiency were compared with
those of a control group, and a comparison of vitamin D deficiency across different diagnostic groups was also
made. Vitamin D deficiency was defined as 25(OH)D <50 nmol/L (<20 ng/ml).
Results: The mean levels of 25(OH)D in the patient group (n = 95) and the control group (n = 104) were 40.5 nmol/L
and 65.9 nmol/L (p < 0.001), respectively. A high prevalence of vitamin D deficiency was found in the patient group
compared with the control group (71.6% and 20.0%, respectively; p < 0.001). After adjusting for age, gender, season,
body mass index, and smoking, vitamin D deficiency was still associated with patient status (OR: 12.95, CI (95%):
6.03-27.83, p < 0.001). No significant differences in the prevalence of vitamin D deficiency were found between patients
with different categories of psychiatric diagnoses, such as depression, bipolar disorders, psychosis, and dementia.
Conclusion: Vitamin D deficiency is very common among psychogeriatric patients, independent of diagnostic
category. Even though the role of vitamin D in psychiatric disorders is still not clear, we suggest screening for vitamin
D deficiency in this patient group due to the importance of vitamin D for overall health.Background
There has been an increase in interest in vitamin D defi-
ciency over the last 10 years. Several studies have re-
vealed a high prevalence of vitamin D deficiency even in
areas of the world that receive ample sunlight. The level
of 25-hydroxyvitamin D (25(OH)D) is used to evaluate
subjects’ vitamin D status. In Australia, India, and Saudi
Arabia, 30-50% of children and adults have 25(OH)D
levels below 50 nmol/L [1-3]. Similarly, in Norway, more
than 40% of the population have been reported to have
serum 25(OH)D levels below 50 nmol/L [4]. Only a few* Correspondence: ole.gronli@unn.no
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unless otherwise stated.types of food naturally contain vitamin D (e.g., salmon,
mackerel, and cod liver oil); therefore, the major source
of vitamin D is sunlight [5]. UVB radiation in the 290–
315 nm wavelength converts 7-dehydrocholesterol in the
skin to previtamin D3, which, in turn, is converted into
vitamin D3. Vitamin D3 is then hydroxylated in the liver
to 25(OH)D and further hydroxylated in the kidneys to
its active form, 1,25 dihydroxyvitamin D (1,25(OH)2D)
[6]. Latitude and season affect the quantity and quality
(wavelength) of solar radiation and thus influence the
ability of sunlight to synthesize vitamin D3 in the skin
[7]. For example, in Edmonton, Canada (52°N), skin ex-
posed to sunlight from October through March pro-
duced no previtamin D3 [7]. Previous studies showed
that elderly individuals produce only 25% of the cutane-
ous vitamin D produced by young adults [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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range of 25(OH)D. Serum levels of 25(OH) D below
50 nmol/L are associated with an increase in serum
parathyroid hormone (PTH) levels [9] and a decrease in
physical performance in older individuals [10]. It has been
suggested that serum 25(OH)D levels above 50 nmol/L
are sufficient to sustain bone density and calcium absorp-
tion and to prevent osteomalacia [11]. This cut-off level is
now widely used in studies of vitamin D deficiency.
Several cross-sectional studies have found an associ-
ation between vitamin D deficiency and depression or
depressive symptoms [12-16]. Despite some negative re-
ports [17], Anglin et al. [18] concluded in a recent meta-
analysis that low vitamin D concentration is associated
with depression, but further randomized controlled trials
(RCTs) of vitamin D are needed to determine whether
this association is causal. There have been a few RCTs
studying the effects of vitamin D on depressive symp-
toms, but the findings are inconsistent [19-21]. A recently
published RCT did investigate the effects of vitamin D
supplementation as adjuvant treatment in patients with
major depressive disorder. The results showed a signi-
ficant improvement in patients being treated with an an-
tidepressant and vitamin D as compared with patients
receiving an antidepressant and placebo [22]. There are
also studies reporting an association between vitamin D
deficiency and cognitive impairment [23-25] and even
psychosis has been associated with vitamin D deficiency
[26-28].
Psychogeriatric patients may be at risk for vitamin D
deficiency due to their age, less exposure to sunlight,
and dietary factors. However, there is little knowledge
regarding the actual vitamin D status in this group of
patients. Therefore, one aim of this study was to com-
pare the level of 25(OH)D in a sample of psychogeriatric
patients with the level in the general elderly popula-
tion from the same area. In addition, the study aimed
to examine whether patients with depression differ from
patients with other psychiatric diagnoses with regard to
vitamin D status.Methods
Study population
The study took place from March 2010 to December
2011. Patients aged 65 years or older who were referred
to a psychiatric hospital located in Tromsø (69°N) in the
northern part of Norway were eligible for inclusion. The
hospital has a population base of 255,000 subjects. Pa-
tients who were not able to communicate due to their
medical condition (i.e., severe dementia) were excluded.
With regard to the controls, subjects older than 64 years
who had participated in a follow-up study after the 6th
Tromsø study and had normal glucose tolerance wererandomly selected and stratified for gender, age, BMI,
and blood sampling season.
Measures
Assessment of psychiatric symptoms
The following instruments were used to diagnose the
participant patients: the Mini International Neuropsychi-
atric Interview (MINI+) [29], the Montgomery-Asberg
Depression Rating Scale (MADRS) [30], the Mini Mental
Status Examination (MMSE) [31], and the Clockdrawing
Test [32]. In addition to the structured diagnostic psy-
chiatric interview (MINI+), clinical interviews and med-
ical records were also used to diagnose the participants.
Patients with dementia (n = 19) who could not parti-
cipate in a MADRS interview were assessed with the
Cornell Scale for Depression in Dementia [33]. Diag-
noses were made according to ICD-10 criteria (WHO,
1992). The control group was not assessed for the pre-
sence of psychiatric disorders.
Laboratory analyses
Blood samples for 25(OH)D were drawn in the morning
before 10 AM during the first 3 days of the hospital stay
and were stored at -70°C. Analyses of 25(OH) D were
performed using a competitive radioimmunoassay (RIA)
(Dia Sorin, Stillwater, MN) [34]. Vitamin D deficiency
was defined as 25(OH) D levels <50 nmol/L. In addition,
analyses of calcium, albumin, PTH, creatinine, erythro-
cyte sedimentation rate (ESR), C-reactive protein (CRP),
glucose, free thyroxine (FT4), and TSH were performed
the same day.
Statistical analyses
The SPSS 20 software package (SPSS Inc., Chicago, Illinois,
USA) was used for statistical analyses. The Kolmogorov-
Smirnov test was used to confirm assumptions of normal
distributions. Baseline differences were analyzed using chi-
square tests (dichotomous data), Mann–Whitney U-test
and independent samples t-tests (continuous data). Logistic
regression models were used to assess the association be-
tween vitamin D deficiency and the sample variables (pa-
tient vs. control), controlling for potential confounders.
The results were expressed as odds ratios (ORs) with 95%
confidence intervals (CIs). The association of vitamin D
deficiency status with psychiatric diagnoses was examined
using the Fisher’s exact test. A correlation between PTH
and 25(OH)D was calculated using Pearson’s correlation
method. A p-value < 0.05 was accepted as statistically sig-
nificant. The data are presented as the mean (SD) unless
otherwise specified.
Ethics and consent
Possible candidates for inclusion in the study were given
oral and written information about the study. The next
















Table 3 Adjusted odds ratio (95% CI) for the association
between vitamin D deficiency and patient/control status
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able to provide informed consent alone due to his/her
medical condition. Written consent (from the patient or
the next of kin) was provided prior to inclusion in the
study. Existing guidelines were used to assess compe-
tency to give consent [35]. The Regional Medical Ethics




A total of 95 patients (90 inpatients and 5 outpatients)
and 104 controls were included in the study, all of whom
were ethnic Norwegians. Basic characteristics of the pa-
tient and control groups are shown in Table 1. The pa-
tients suffered from a range of disorders that are typical
in a psychogeriatric population (Table 2). We found that
40 patients had a depressive disorder, either as a first-
time depressive episode, recurrent depression or as part
of a bipolar disorder. We also identified 18 patients with
depression secondary to other diagnoses (e.g., dementia
or organic mood disorder). In 37 of the patients no de-
pressive disorders were identified. In this sub-group, 18
patients had dementia (14 with Alzheimer’s disease), 11
patients had a psychotic disorder, and 8 patients had
other non-depressive disorders.
Serum 25(OH)D levels
The mean (SD) serum 25(OH)D levels were 40.5 (19.0)
nmol/L, which was significantly lower than the control
group’s of 65.9 (19.5) nmol/L (t(198) = −9.19, p < 0.001).
In the patient group, 68 patients (71.6%) had vitamin D
deficiency (serum 25(OH)D <50 nmol/L), as compared
with only 21 individuals (20.0%) in the control group
(χ2 = 53.7, p < 0.001). Severe vitamin D deficiency (25
(OH)D <25 nmol/L) was observed in 18 patients (19.4%)
and 2 individuals (1.9%) in the control group (p < 0.001).
There was no significant gender difference between
the mean 25(OH)D levels neither in the patient group
(women: 40.7 nmol/L, men: 40.3 nmol/L) or in the con-
trol group (women: 63.3 nmol/L, men: 69.4 nmol/L). In
a multivariate model that included age, gender, BMI,Table 1 Clinical characteristics of the patient and
control groups
Patients Controls p-value
Gender % (female/male) 63.2/36.8 62.9/37.1 p = 0.965*
Age, mean (SD) 77.2 (6.5) 74.6 (1.3) p = 0.002**
Smoking (%) 29.3 17.1 p = 0.042*
BMI (kg/m2), mean (SD) 25.3 (5.4) 25.9 (4.1) p = 0.330***
Blood sampling season (winter,
spring, summer, autumn) (%) 18/28/26/27 25/28/28/20 p = 0.515*
Notes: *χ2 = Chi-square test, **Mann–Whitney U-Test, ***Student’s t-test.smoking, and blood sampling season, only patient status
and blood sampling season were predictive of vitamin D
deficiency (Table 3).
Serum 25(OH)D levels and psychiatric diagnoses
In the patient group, we did not find any significant dif-
ference in 25(OH)D levels between patients with depres-
sion as the main diagnosis, patients with depression as
part of other diagnoses, and patients with another psy-
chiatric diagnosis (Figure 1). Furthermore, when group-
ing the patients into five diagnostic categories (unipolar
depression, bipolar depression, psychosis, dementia, and
other diagnoses), there were still no significant differ-
ences in serum 25(OH)D levels between the groups
(Table 4). There was a small, but significant correlation
between MADRS score and serum 25(OH)D levels (rs = .26,
p = 0.028).OR (95% CI) p
Patient/control 12.95 (6.03-27.83) p <0.001
Sex 1.55 (0.76-3.16) p = 0.231
Age 0.99 (0.92-1.07) p = 0.876
Winter* p = 0.067
Spring 0.61 (0.23-1.62) p = 0.319
Summer 0.27 (0.10-0.75) p = 0.012
Autumn 0.36 (0.13-1.04) p = 0.060
BMI 0.94 (0.87-1.83) p = 0.085
Smoking 0.79 (0.34-1.83) p = 0.581
Notes: *season for blood sampling.
Figure 1 Serum 25(OH)D levels (nmol/L) in subjects with
depression, comorbid depression, and other psychiatric
diagnoses.
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ces used, namely, cod fish oil (a common supplement in
Norway), vitamin D tablets (multivitamin), or vitamin
D-fortified milk. We found that 39 patients (41%) took
some type of vitamin D supplement, 44 patients (46%)
did not take any supplement, and vitamin D source data
were missing for 12 patients. There was no significant
difference in 25(OH)D levels between the patient group
that reported an intake of extra vitamin D and the group
with no intake of extra vitamin D (mean 25(OH)D levels
were 42.2 nmol/L and 36.2 nmol/L, respectively). Fur-
thermore, there was no significant association between
vitamin D deficiency and intake of a vitamin D supple-
ment. We also had data on the average time spent out-
doors over the 3 months before study inclusion. There
was no significant difference in 25(OH)D levels between
patients who spent less than 30 min outdoors every day
(n = 61, mean serum 25(OH)D = 39.5 nmol/L (17.2)) and
patients who spent more than 60 min outside every day
(n = 17, serum 25(OH)D = 34.0 nmol/L (14.0)). As ex-
pected, there were seasonal variations in vitamin D sta-
tus, with higher levels present in summer and autumn.
This result was a trend in both the patient and controlTable 4 Serum 25(OH) D levels and prevalence of vitamin
D deficiency in relation to diagnoses
Diagnoses N 25 (OH) level (nmol/L)1 Prevalence (%) of
vitamin D deficiency2
Depression 31 45.9 (20.5) 71.0
Bipolar disorder 10 43.8 (18.0) 50.0
Psychosis 12 33.9 (16.0) 83.3
Dementia 31 38.6 (18.6) 74.2
Other diagnoses 11 34.8 (17.6) 72.7
1A one-way ANOVA test revealed no significant difference (F(4,90) = 1.41,
p = 0.236) in 25(OH)D levels between the different diagnostic groups.
2The Fisher’s exact test indicated no significant association (χ2 = 3.1, p = 0.522)
between vitamin D deficiency and diagnosis.groups (Figure 2), but the differences in serum 25(OH)D
level between different seasons were not statistically
significant.
A total of 26% of the patients had elevated PTH levels
(>7.5 pmol/L), and there was a negative correlation be-
tween serum 25(OH)D and PTH levels (r = −0.34, p <
0.001). We did not have data on PTH in the control
group. Neither the correlation between serum 25(OH)D
levels and MMSE (rs = −.11, p = 0.297) or with Clock-
drawing Test scores in the patient group (rs = .07, p =
0.508) were significant.
Discussion
In this study, we found a high prevalence (71.6%) of vita-
min D deficiency in elderly psychiatric patients com-
pared with a control group (19.2%). We could not find
any difference in vitamin D deficiency between patients
in different diagnostic groups. Although this study was
conducted in the northern part of Norway, vitamin D
deficiency is a common problem in other parts of the
world as well. Van der Wielen et al. found that among
the elderly, vitamin D deficiency was more common in
southern Europe than in Scandinavia [36]; therefore, our
findings seem to be relevant globaly.
Our results are in line with those of other studies. In a
group of psychogeriatric inpatients, Lapid et al. found
no association between 25(OH)D level and psychiatric
diagnosis [37], and the same findings were reported in a
non-elderly group [38]. A Swedish study of adult psy-
chiatric outpatients reported low levels of 25(OH)D (me-
dian 45 nmol/L), with slightly lower levels in patients
with schizophrenia and autism compared with other
diagnoses [39]. However, we are not aware of any studies
that have examined the difference in levels of 25(OH)D
between a control group and psychogeriatric patients
with a wide range of psychiatric disorders.
There are several possible explanations for our findings.
On the one hand, it is possible that older individuals withFigure 2 Serum 25(OH)D levels in relation to season.
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tern that may result in vitamin D deficiency, which could
also be the case for different diagnostic groups, not only
depressed patients. The hospital associated with this study
is located at high latitude in the northern part of Norway,
where there is no sun-induced production of vitamin D in
the skin for more than 6 months of the year [7]. This pa-
tient group could thus be even more vulnerable to vitamin
D deficiency due to a diet low in vitamin D. On the other
hand, one cannot rule out the possibility that vitamin D
deficiency can contribute to the development of several
psychiatric disorders. It is well known that a diversity of
psychiatric symptoms can occur in connection with vari-
ous medical conditions. Some patients with thyrotoxicosis
develop depression, others develop anxiety or psychosis,
and some do not develop psychiatric disorders at all [40].
The same pattern is found in patients with hyperparathyr-
oidism [41] and in patients with low levels of vitamin B12
[42]. These results suggests that there could be some un-
known individual factors that make some people more
vulnerable than others to the development of various psy-
chiatric symptoms due to alterations in these hormones
and micronutrients. Although we could not find a signifi-
cant difference in serum 25(OH)D levels between different
diagnostic groups, we can not rule out the possibility of a
type II error, due to modest number of subjects in some
of our diagnostic sub-groups.
Several human and animal studies have suggested pos-
sible biological explanations for the importance of vita-
min D in psychiatric disorders. Vitamin D receptors and
the enzyme required for its activation, 1α hydroxylase,
have been identified in the human brain [43]. Active
vitamin D (1,25(OH)2D) is shown to alter cholinergic,
dopaminergic, and noradrenergic neurotransmitter sys-
tems in animal models [44]. Abnormalities of these neuro-
transmitters have been linked to various neuropsychiatric
disorders [45]. Groves et al. studied the impact of adult
vitamin D deficiency in two strains of mice [46], and a
small reduction in an enzyme involved in GABA synthesis
(GAD65/67) was reported. Altered GABAergic neuro-
transmission has been linked to several psychiatric con-
ditions, including schizophrenia [47], anxiety [48], and
depression [49]. In the most neophobic strain (BALB/c
mice), Groves et al. also found alterations in glutamate
and glutamine levels in brain tissue, which may indicate a
disruption in glutaminergic neurotransmission. NMDA
receptor (glutamate receptor) dysfunction has been linked
to several psychiatric conditions, including depression and
schizophrenia [50,51].
As expected, there was a significant negative correl-
ation between serum 25(OH)D and PTH levels [9,52].
High levels of PTH have been associated with impaired
performance in cognitive tests [53] and with depression
[52]. Primary hyperparathyroidism with elevated PTHand calcium can present with a variety of psychiatric
symptoms [41], and we previously reported that this
may be due to elevated PTH and not elevated calcium
[54]. It is therefore possible that an effect of vitamin D
on psychiatric symptoms could be indirectly caused by
elevated PTH levels.
There was no significant difference in vitamin D levels
between patients who reported taking a vitamin D sup-
plement and patients who reported not taking a vitamin
D supplement. These data are based on patients’ self-
reporting and thus it is difficult to draw any firm conclu-
sions. However, the finding could strengthen the impression
that the recommended supplement dose of vitamin D in
Norway (400 IE vitamin D3) is not enough to maintain an
adequate level of vitamin D in elderly individuals, and se-
veral authors have recommended 800–1000 IE vitamin D3
as a daily supplement for the elderly [6,55,56].
Although the role of vitamin D in psychiatric disorders
is not clear, there are also other reasons to be aware of
vitamin D deficiency. A meta-analysis of 17 randomised
trials demonstrated a 12% risk reduction in fractures in
patient groups receiving calcium and vitamin D supple-
ments [57]. Vitamin D deficiency can cause proximal
muscle weakness and muscle pain [58]. Vitamin D sup-
plements increase muscle strength and balance and re-
duce the risk of falling [59,60]. In observational studies,
vitamin D deficiency has also been associated with an in-
creased risk of several other conditions, including cancer,
diabetes, and multiple sclerosis, as well as a higher overall
mortality rate and premature aging [6,61-63]. However, a
recent review by Autier et al., found that intervention
studies did not show an effect of vitamin D supplementa-
tion on non-skeletal health outcome whereas observa-
tional studies did. An exception was slightly reduced
all-cause mortality [64]. The authors proposed that this
difference in outcome might indicate that low 25(OH)D is
a marker for ill health [64].
Our current study has some limitations. A reverse
causality cannot be ruled out in this type of study design,
as we do not know whether vitamin D deficiency is a
contributor or a consequence of psychiatric disorders. In
the control group, we did not have data to assess med-
ical comorbidity, and therefore, we were not able to con-
trol for ill health as a possible confounder. We did not
have data on the amount of time spent outdoors, use of
vitamin D supplements, or psychiatric symptoms in the
control group. It is unlikely, however, that elderly patients
with significant mental distress participated in the popula-
tion survey. Hansen et al. found that non-attendees in a
survey had a 2.5-fold higher prevalence of psychiatric dis-
orders compared with attendees [65]. In the patient group,
there may also have been some recollection bias when the
patients were asked about vitamin D supplementation and
time spent outdoors.
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Although our study did not address the issue as to
whether the observed differences represent a causal re-
lationship between vitamin D deficiency and psychiatric
symptoms, the results are nonetheless important given
the significance of vitamin D to overall health. We sug-
gest that increased attention should be given to vitamin
D deficiency in elderly patients with psychiatric disor-
ders. Serum 25(OH)D assessment should be included in
the set of standard blood tests performed in this patient
group and treatment with vitamin D should be initiated
in patients with low serum 25(OH)D. There is mounting
evidence suggesting that vitamin D could have an impact
on a variety of psychiatric conditions; however, more
RCTs are needed to address the question of causality.
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